Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Ticagrelor treatment strategies comparative analysis in primary percutaneous coronary intervention
Session:
Painel 8 - Doença Coronária 3
Speaker:
Luís Graça Santos
Congress:
CPC 2020
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
14. Acute Cardiac Care
Subtheme:
14.2 Acute Cardiac Care – Prehospital and Emergency Department Care
Session Type:
Posters
FP Number:
---
Authors:
Luís Graça Santos; Rita Ribeiro Carvalho; Sara Lopes Fernandes; Fernando Montenegro Sá; Catarina Ferreira Ruivo; Francisco Soares; Joana Correia; Sidarth Pernencar; Joao Morais
Abstract
<p><strong>Introduction:</strong> There is some evidence favouring clopidogrel pretreatment in ST-elevation myocardial infarction (STEMI) patients (pts) undergoing primary PCI (pPCI). However, prasugrel has not been studied in this setting and a randomized trial with ticagrelor showed disappointing results.</p> <p><strong>Aim: </strong>To investigate the effect of ticagrelor pretreatment on clinical outcomes of pts undergoing pPCI.</p> <p><strong>Methods: </strong>Retrospective multicentre study of 3968 STEMI pts who underwent pPCI between January 2013 and December 2018. Patients with prior chronic exposure to oral antithrombotics (except acetylsalicylic acid), not acutely managed with ticagrelor, and those with missing data were excluded. A total of 382 pts were included for analysis, 327 (85.6%) received ticagrelor pretreatment (Group 1) and 55 (14.4%) were treated with ticagrelor only in the catheterization laboratory (Group 2). The primary endpoint of the study was related to reperfusion outcomes and defined as a composite of pPCI failure (post dilation Thrombolysis in Myocardial Infarction flow grade <3), bailout use of GIIb/IIIa inhibitors or need for aspiration thrombectomy. The secondary safety endpoint was a composite of in-hospital major bleeding, need for red blood cell transfusion or haemoglobin drop ≥2g/dL, and the tertiary endpoint was a composite of in-hospital all-cause death, stroke or re-infarction. Multivariate analysis was performed to determine the correlates of ticagrelor pretreatment and each of the endpoints. One-year follow up was achieved in 47 pts (12.3%).</p> <p><strong>Results: </strong>Overall, mean age was 61±12 years and 23.8% were female. Crude event rates did not differ regarding both primary (31.1 vs 38.5%; p=0.29) and tertiary (2.8 vs 5.5%; p=0.39) endpoints, while secondary safety endpoint was more frequent among group 1 (35.2% vs 18.2%; p=0.03). Multivariate analysis showed no differences regarding both primary and secondary endpoints (Figure 1A). At the Kaplan-Meier analysis, one-year cumulative event-free (all-cause death, stroke or re-infarction) rates did not differ (Figure 1B).</p> <p><strong>Conclusion:</strong> In this cohort of STEMI pts undergoing pPCI, reperfusion related outcomes and safety profile did not differ according to the timing of ticagrelor administration. Regarding these results and until more consistent data is available, ticagrelor pretreatment may be used although benefit remains unclear.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site